Search Results

Discover how Celtarys Research is transforming GPCR assay development with fluorescent ligands in this At Celtarys, the focus is on enabling fast, customizable development of fluorescent ligands and chemical development. Their approach is highly consultative—they don’t just sell ligands, they co-develop solutions. GPCR ecosystem , GPCR drug discovery , fluorescent ligands , GPCR scientist network , custom ligand development

🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We

Got hooked on ligand design. Dr. Maria Majellaro didn’t plan to run a biotech company. Now she’s leading Celtarys, building custom fluorescent probes, and partnering with Dr. GPCR to support assay development worldwide. Now she’s leading Celtarys, building custom fluorescent probes, and partnering with Dr. GPCR to support assay development worldwide.

Home → Flash News → 🚀 Ready to dive into the world of GPCR drug development? Join Dr. Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

Home → Flash News → 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development—and registration closes in 3 days! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

We also offer our expertise in the form of custom development services, where we tackle challenging targets technology and accelerate the development of GPCR-targeted therapeutics. Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology Custom Development Customized fluorescent ligands developed in less than 3 months with optimal properties Custom Development Tailored fluorescent probes designed for unique research requirements.

Check out the development of a NanoBRET assay platform to detect intracellular ligands for the chemokine Check out the development of a NanoBRET assay platform to detect intracellular ligands for the chemokine ➡️ https://www.ecosystem.drgpcr.com/methods-and-updates-in-gpcr-research/development-of-a-nanobret-assay-platform-to-detect-intracellular-ligands-for-the-chemokine-receptors-ccr6

Home → Flash News → In case you haven’t heard, registrations are open for the next 4-week course “Development with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs GPCR Courses In case you haven’t heard, registrations are open for the next 4-week course “Development with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

“Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

Home → Flash News → 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

GPCR to expand fluorescent ligand tools for GPCR drug discovery, connecting biotech startups and scientists Learn more about new ligands and new GPCR behaviors that produce unique drug profiles. Learn more about new ligands and new GPCR behaviors that produce unique drug profiles. ✳️ Last chance

announce our strategic partnership with Celtarys Research, a biotech company specializing in fluorescent ligand with Celtarys’ innovative chemical biology tools, making it easier than ever for scientists to study ligand-receptor announce our strategic partnership with Celtarys Research , a biotech company specializing in fluorescent ligand affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

Home → Flash News → 🚨 Exciting Opportunity for Professionals in Drug Development! GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 : Thursdays, 10:00 AM - 11:30 AM (EST) This advanced course is essential for anyone working in drug development GPCR Courses 🚨 Exciting Opportunity for Professionals in Drug Development! GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025

One example of our recent work surrounds a structure-based effort to develop ligands that specifically Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy We have identified several GPCR ligands that allosterically modulate orthosteric ligand binding and target The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and Through structural and computational approaches the Sunahara lab and collaborators developed a thermostable

Together with Irina Kufareva , UCSD, her team developed a novel approach to identifying ligands for orphan GPCRs by developing a powerful new computational tool for identifying ‘surrogate’ ligands (borrowed inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic targets with high-affinity ligands

“Let’s embrace the challenge to study all of them… they’re unique in how they bind ligands, how selective With hundreds of subtypes and very few known ligands, the structure–function relationships remain largely “The main challenge was: how do we get a face for these proteins when we don’t have ligands?” Build predictive models to discover new ligands . 8. Alessandro PhD work aims to fill these gaps by leveraging computational structure-based tools and develop

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics and provides you with cell-based assay solutions for basic research through therapeutic discovery and development Assay Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic drugs, Eurofins DiscoverX provides you with a variety of drug discovery and development product solutions represent the foundation of tools for GPCR research and drug discovery and development

New simulations reveal the conformational changes from inactive to active states to highlighting how ligand New simulations reveal the conformational changes from inactive to active states to highlighting how ligand

Known for their fluorescent ligand innovation, Celtarys is helping researchers make biology visible, Known for their fluorescent ligand innovation, Celtarys is helping researchers make biology visible,

🚀 Learn the practical issues with detecting, measuring, and quantifying GPCR ligand-biased signaling 🚀 Learn the practical issues with detecting, measuring, and quantifying GPCR ligand-biased signaling affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

Lefkowitz , where his research focused on biased agonism, with the development of approaches to quantify ligand bias and the identification of beta-arrestin-biased receptors. The chemokine system is relatively unique in having multiple receptors and multiple ligands that display His group and others have shown that many of these ligands act as biased agonists for the same receptor

Then, with Celtarys, the team did the same for ligand-linker-fluorophore chemistry. Then, with Celtarys, the team did the same for ligand-linker-fluorophore chemistry.

My project involved the development of FRET/BRET -based GPCR conformational biosensors, which can be employed in high throughput ligand screening. I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors recently awarded a Marie Sklodowska Curie PostDoc Fellowship in order to investigate and find better ligands

→ Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand News Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand

Different ligands stabilize distinct receptor states, leading to diverse signaling outcomes. Drug Disposition in Physiological Tissues as a Therapeutic Variable Lecture 3: The Application of GPCR Ligand Kinetics to Candidate Design Lecture 4: Unconventional GPCR Ligands as Drugs Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit Terry Kenakin 🔒 Premium Content Watch recording Principles Aside from his vast experience in drug development, not to mention his extensive publication record,

early discoveries in cyclic AMP signaling to uncovering ultrasensitive receptor responses at femtomolar ligand This conversation is especially valuable for scientists developing functional assays, fluorescence-based The moment when femtomolar ligand concentrations uncovered unexpected receptor sensitivity. lab structure at Monash Institute of Pharmaceutical Sciences fosters innovation in functional assay development Get behind-the-scenes conversations, advanced assay development strategies, and practical GPCR tools

orthosteric vs allosteric function, and real vs apparent affinity • Molecular dynamics and how they guide ligand orthosteric vs allosteric function, and real vs apparent affinity 🟢 Molecular dynamics and how they guide ligand

Since starting my laboratory in 2011, I has focused on G protein coupled receptors, in particular, the ligand Our first main research aspect is the identification of endogenous ligand of GPCRs. We also identified DHEA, DHEAS and DOC are endogenous ligands of GPR64 etc (Nature, 2021a, Nat Chem Biol Our fourth main research aspect is ligand coding mechanisms and structural aided drug discovery of GPCR